Healthcare ❯ Pharmaceuticals

Biopharmaceuticals

Drug Development Clinical Trials Product Development Therapeutics Generic Drugs Research and Development Generic Medicines Radiopharmaceuticals Bristol-Myers Squibb Company Pulmonary Arterial Hypertension Immunology Rare Diseases Clinical-stage Biopharmaceutical Companies Insmed Respiratory Diseases Duchenne Muscular Dystrophy Oncology Corporate Acquisitions Ophthalmology Oncology Treatments Cardiovascular Treatments FDA Approvals Vaccines Animal Health Product Launches Teva Pharmaceutical Industries Limited

Telix Investors Face Jan. 9 Deadline in Securities Class Action Tied to SEC, FDA Disclosures

Plaintiff firms are pressing affected shareholders to seek lead-plaintiff status before the court’s cutoff.

Telix Investors Face Jan. 9 Deadline in Securities Suit Over Drug and Manufacturing Disclosures

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Bristol Myers and J&J Cast as Dividend Plays as Bayer’s FXIa Win Refocuses Pipeline Interest

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

PGIM Jennison’s Q2 Letter Details Health-Care Slide, Portfolio Shifts and Company Catalysts

BMO Raises AbbVie Target to $240 After Rinvoq Generic Dispute Is Resolved

Teva Wins FDA Fast Track for Emrusolmin in Multiple System Atrophy

Biohaven Investors Face Sept. 12 Deadline in Securities Class Action